StockData
argenx SE logo

argenx SE (ARGX) company profile

ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 19, 2026Score 5/30
$960.04−21.29 (-2.17%)

Close on Nov 13, 2026Market cap –P/E 49.1Yield –

About argenx

Biological Products, (No Diagnostic Substances), SIC 2836

The provided filing excerpt contains raw XBRL taxonomy identifiers and accounting data tags without any narrative corporate descriptions. Consequently, the excerpt does not disclose the company's business activities, main products, commercial services, operating segments, or customer base. The taxonomy references include equity items, share-based payment plans, and asset categories, but omit descriptive operational context.

The excerpt also provides no operational metrics, facility counts, geographic presence, or corporate headquarters location. While accounting tags reference Belgian tax regulations in the context of share awards, no geographic reach or headquarters details are disclosed in the text. Furthermore, the text does not state the founding year or an official website address.

Summary of the business section of argenx's latest annual report, written by StockData.

Company profile

Company

Legal name
argenx SE
Headquarters
Zwijnaarde, Belgium
Address
Industriepark Zwijnaarde 7, Building C B-9052
Phone
(329) 310-3400
Website
argenx.com
Employees
1,863, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
P7
Fiscal year ends
December 31
Auditor
EY Accountants B.V., Eindhoven, the Netherlands

Stock & identifiers

Ticker
ARGX
Exchange
Nasdaq
IPO date
May 19, 2017
Shares outstanding
62M, Dec 31, 2025
Filer category
Large accelerated filer
SEC CIK
1697862
CUSIP
04016X101
ISIN
US04016X1019
FIGI
BBG00GHB88X9
Share class FIGI
BBG00GHB88Y8
LEI
7245009C5FZE6G9ODQ71
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

argenx's leadership is listed in its proxy statement (Form DEF 14A).

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 19, 2017
Offer price
$17.00
Securities offered
5,865,000
Gross proceeds
$99.71M
Exchange
Nasdaq
First trading day
May 18, 2017
First-day close
$23.00+35.3%
Lock-up ends (est.)
Nov 14, 2017

“Per ADS Total Initial public offering price $ 17.00 $ 99,705,000 Underwriting discounts and commissions(1) $ 1.19 $ 6,979,350 Proceeds, before expenses, to argenx SE $ 15.81 $ 92,725,650 (1) We refer you to "Underwriting" beginning on page 292 of this prospectus for additional information regarding underwriting c”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“• Expansion to 1,863 full-time employees (as of December 31, 2025) to support further growth of our business,”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 6, 2026Tender offerThird-party tender offer for the company's shares
May 19, 2017IPOInitial public offering priced (424B4 prospectus)
May 16, 2017ListingRegistration of securities on an exchange (Form 8-A)
Apr 21, 2017Name changeName changed from argenx N.V to argenx SE

See a number that looks wrong?